|Jun 05, 2007
|ELITE PHARMACEUTICALS TO PRESENT AT FTN MIDWEST SECRUITIES 2007 HEALTHCARE CONFERENCE
|Northvale, New Jersey, Tuesday, June 05, 2007: Elite Pharmaceuticals, Inc.(AMEX: ELI), a pharmaceutical company that develops and manufactures oral controlled-release products, announced today that Chris Dick, Executive Vice President of Corporate Development will provide an overview of the company's business at the FTN Midwest Securities 2007 Healthcare Conference at the Four Seasons Hotel in New York, New York on Wednesday, June 6, 2007 at 2:30 PM Eastern Time.
The presentation will webcast live and can be accessed through Elite Pharmaceutical's website, www.elitepharma.com.
An archived version will be available for 90 days after the live presentation and can be accessed at the same location.
About Elite Pharmaceuticals
Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacturing of oral controlled-release products. Elite's technology is applicable to develop delayed, sustained or targeted release capsules or tablets. Elite has a pipeline of seven drug products under development in the therapeutic areas that include pain management, allergy, cardiovascular disease and infection. Elite’s lead pipeline products are once-daily oxycodone to provide improved delivery of the drug for the patient and an abuse-resistant oxycodone formulated to discourage the illegal diversion and abuse of this drug. The addressable market for Elite's current pipeline of products exceeds $6 billion. Elite has a strategic alliance with newly formed Novel Laboratories, Inc., which will serve as a separate specialty pharmaceutical company for the research and development, licensing and acquisition of specialty generic pharmaceuticals under CEO Dr. Veerappan Subramanian. Elite also has a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of the Company, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The Company undertakes no obligation to update any forward-looking statements.